Evaluating the Safety and Efficacy of BioTTT001 in Patients With Recurrent/Progressive High-grade Glioma.
Clinical trial NCT06763965 · ENROLLING_BY_INVITATION
Trial details
- NCT number
- NCT06763965
- Sponsor
- Beijing Bio-Targeting Therapeutics Technology Co., Ltd
- Status
- ENROLLING_BY_INVITATION
- Phase
- Phase 1, Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2024-11-26
- Primary completion
- 2027-07-31
- Enrollment
- 30
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.